Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India
· Delayed Price · Currency is INR | Market Cap | 235.90B |
| Revenue (ttm) | 26.63B |
| Net Income (ttm) | 5.28B |
| Shares Out | 167.11M |
| EPS (ttm) | 31.63 |
| PE Ratio | 44.64 |
| Forward PE | 40.86 |
| Dividend | 14.00 (0.99%) |
| Ex-Dividend Date | Feb 5, 2026 |
| Volume | 121,646 |
| Average Volume | 335,791 |
| Open | 1,416.00 |
| Previous Close | 1,416.00 |
| Day's Range | 1,403.40 - 1,428.70 |
| 52-Week Range | 1,272.60 - 1,770.00 |
| Beta | 0.10 |
| RSI | 53.84 |
| Earnings Date | Apr 30, 2026 |
About Dr. Lal PathLabs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]
Financial Performance
In fiscal year 2025, Dr. Lal PathLabs's revenue was 24.61 billion, an increase of 10.54% compared to the previous year's 22.27 billion. Earnings were 4.87 billion, an increase of 36.17%.
Financial StatementsNews
Petronet LNG, HDFC Bank & more: Top stocks to watch today
Nomura cut Petronet LNG's target price due to West Asia crisis impacting volumes, while HSBC maintained a hold on Blue Star, citing demanding valuations. BofA Securities remains constructive on HDFC B...
Dr Lal PathLabs share in focus as CLSA sees ~17% upside on volume-led growth
Shares of Dr Lal PathLabs are in focus after CLSA maintained an Outperform rating on the stock with a target...
Dr. Lal PathLabs Ltd (BOM:539524) Q3 2026 Earnings Call Highlights: Steady Revenue Growth Amid ...
Dr. Lal PathLabs Ltd (BOM:539524) Q3 2026 Earnings Call Highlights: Steady Revenue Growth Amid Strategic Investments
Q3 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Q3 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Dr. Lal PathLabs Transcript: Q3 25/26
Revenue grew 10.6% YoY in Q3 FY26, with strong EBITDA margin of 27.2% and robust cash reserves. Preventive health packages and digital initiatives drove growth, while patient volume was impacted by lower seasonal fever cases. Management maintains 11%-12% organic growth guidance.
Earnings To Watch: Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Reports Q3 2026 Result
Earnings To Watch: Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Reports Q3 2026 Result
Dr. Lal PathLabs fixes December 19 as record date for 1:1 bonus issue
Dr. Lal PathLabs Ltd has announced that its Board of Directors has fixed Friday, December 19, 2025, as the record...
Dr. Lal PathLabs Ltd (BOM:539524) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Dr. Lal PathLabs Ltd (BOM:539524) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
Q2 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Q2 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Dr. Lal PathLabs Transcript: Q2 25/26
Q2 FY26 saw 10.7% revenue growth and 16.4% PAT growth year-over-year, with strong margins and broad-based performance. Investments in digital, AI, and high-end diagnostics, plus disciplined network expansion, support sustained growth. Interim dividend and 1:1 bonus issue announced.
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 2026 Earnings Report Preview: What To Expect
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 2026 Earnings Report Preview: What To Expect
Dr. Lal PathLabs Transcript: Q1 25/26
Q1 FY26 saw 11.3% revenue growth and 24.3% profit after tax increase, driven by higher volumes, favorable test mix, and expansion in bundled and specialized testing. Guidance for 11–12% revenue growth is maintained, with margins expected to remain strong.
Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market
Shares of diagnostic service providers Dr Lal PathLabs and Metropolis Healthcare slipped in Monday’s trade following Amazon India’s announcement of its foray into the diagnostics space. Amazon launche...
Dr Lal PathLabs shares decline 2% as Amazon enters diagnostics segment with doorstep lab tests
Shares of Dr Lal PathLabs fell over 2% to Rs 2,849.00 on Monday after Amazon India announced the launch of its diagnostics service in collaboration with Orange Health Labs. The new offering is expecte...
Dr. Lal PathLabs Earnings Call Transcript: Q4 2025
Revenue grew 10.5% in FY 2025, outpacing industry, with strong expansion in labs and digital infrastructure. FY 2026 guidance targets 11-12% revenue growth and ~27% EBITDA margin, as investments continue in new geographies and advanced diagnostics.
Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY
Dr. Lal PathLabs Ltd reported a strong financial performance for the fourth quarter ended March 31, 2025, with consolidated net profit rising 81% year-on-year to ₹155.5 crore, up from ₹85.8 crore in Q...
Dr. Lal PathLabs Transcript: Q3 24/25
Q3 FY25 saw 10.7% revenue growth, strong Delhi NCR performance, and Swasthfit packages up 27.2% YoY. Expansion continues in Tier 2/3/4 markets, with a focus on volume growth, digital infrastructure, and high-end diagnostics. Net cash stands at INR 1,123 crore.
Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls
Shares of Dr Lal Path Labs surged by 3.46%, rising ₹112.75 to trade at ₹3,368.45 on the NSE at 9:16 AM. The stock’s upward movement follows the release of strong Q2 FY25 earnings and positive brokerag...
Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying
Several brokerages have shared their views on Dr Lal Path Labs. Here’s what they are saying: Goldman Sachs: Goldman Sachs has maintained its sell call on Dr Lal Path and raised the share price target ...
UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price
UBS has maintained its buy rating on Dr LalPath Labs, with a share price target of ₹3,500, indicating a 7.7% upside from the current market price (CMP). The company’s Q2 performance was robust, showin...
Dr. Lal PathLabs Transcript: Q2 24/25
Q2 FY25 saw 9.8% revenue growth and 18.1% PAT growth, driven by bundled test packages and network expansion, with margins and cash position remaining strong. Guidance for FY25 is maintained at or above last year’s growth, with continued investments in technology and expansion.
Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore
Dr Lal PathLabs has reported solid financial results for Q2 FY25, showing notable growth in both revenue and net profit on a year-on-year (YoY) basis. Key Financial Highlights: Revenue for Q2 FY25 sto...
Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720
Nomura has maintained its ‘Buy’ rating on Dr Lal PathLabs, setting a target price of ₹3,720, which implies a potential upside from the current market price of ₹3,280. Nomura expects steady performance...
Dr. Lal PathLabs Transcript: Q1 24/25
Q1 FY 2025 saw 11.3% revenue growth, strong profitability, and robust expansion in Tier 3/4 towns. Suburban Diagnostics integration and digital investments are progressing, with specialized and wellness portfolios driving growth. Cash reserves support dividends, acquisitions, and infrastructure.